IOBT

No price yet

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

IO Biotech to announce topline results of pivotal Phase 3 trial of Cylembio® in combination with KEYTRUDA® as first-line treatment for advanced melanomaAug 11, 2025
IO Biotech announces clinical improvement in progression-free survival demonstrated in pivotal Phase 3 trial of Cylembio plus KEYTRUDA for first-line advanced melanoma, narrowly missing statistical significanceAug 11, 2025